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Teemu J. Murtola1,2, Ville JY Vihervuori1, Jorma Lahtela3, Kirsi Talala4, Kimmo Taari5, Teuvo LJ Tammela1,2 and Anssi Auvinen6
BACKGROUND: Diabetic men have lowered overall risk of prostate cancer (PCa), but the role of hyperglycaemia is unclear. In this
cohort study, we estimated PCa risk among men with diabetic fasting blood glucose level.
METHODS: Participants of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) were linked to laboratory
database for information on glucose measurements since 1978. The data were available for 17,860 men. Based on the average
yearly level, the men were categorised as normoglycaemic, prediabetic, or diabetic. Median follow-up was 14.7 years. Multivariable-
adjusted Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for prostate cancer overall
and separately by Gleason grade and metastatic stage.
RESULTS: In total 1,663 PCa cases were diagnosed. Compared to normoglycaemic men, those men with diabetic blood glucose
level had increased risk of PCa (HR 1.52; 95% CI 1.31–1.75). The risk increase was observed for all tumour grades, and persisted for a
decade afterwards. Antidiabetic drug use removed the risk association. Limitations include absence of information on lifestyle
factors and limited information on BMI.
CONCLUSIONS: Untreated diabetic fasting blood glucose level may be a prostate cancer risk factor.
British Journal of Cancer (2018) 118:1248–1254; https://doi.org/10.1038/s41416-018-0055-4
INTRODUCTION
The relationship between established type 2 diabetes mellitus
(DM) and different types of cancer has been investigated broadly.
Studies have shown that people with DM have lower risk of
developing prostate cancer (PCa) compared with non-diabetics.1, 2
This may be due to altered hormone milieu in diabetic men or
lower prostate-specific antigen (PSA) leading to less prostate
biopsies due to elevated PSA. However, it is not clear whether
this concerns also poorly differentiated PCa, as some studies have
suggested that the risk could be elevated.3 Glucose metabolism
may have an independent role in prostate cancer development
and progression.4, 5 There is evidence that hyperglycaemia and
poor glycaemic control and the related hyperinsulinaemia could
be the possible links.6–8 Yet there are very few studies
concentrating on connections between PCa and blood glucose
levels and glycaemic control, and the results from available studies
are conflicting. Some have reported increased risk of advanced or
aggressive PCa among men with higher glucose levels,9 while
other studies have reported a protective association between
hyperglycaemia and PCa.4, 10 Indirect support for the role of
hyperglycaemia as PCa risk factor comes from studies reporting
lowered risk among men using antidiabetic drugs, particularly
metformin.11Author surnames have been highlighted - please
check these carefully and indicate if the first name or surname
have been marked up incorrectly. Please note that this will affect
indexing of your article, such as in PubMed.
In this study, we investigated the associations between fasting
blood glucose and glycaemic control (glycated haemoglobin,
HbA1c) and PCa risk overall and by Gleason grade and tumour
stage in a cohort of men participating in The Finnish Randomized
Study of Screening for Prostate Cancer (FinRSPC),12 the largest
component of European Randomized Study of Screening for
Prostate Cancer (ERSPC).13 The main goal of FinRSPC and ERSPC
studies was to find out if systematic screening can decrease
prostate cancer mortality. A significant reduction in PCa mortality
was observed in the ERSPC study, though with overdiagnosis
of well-differentiated prostate cancer. In the FinRSPC study the
reduction in PCa mortality was smaller and not statistically
significant.12
MATERIALS AND METHODS
Study cohort
The Finnish Randomized Study of Screening for Prostate Cancer
(FinRSPC) is the largest component of the multinational European
Study of Prostate Cancer Screening (ERSPC).13 In the FinRSPC, all
men aged 55–67 from Tampere and Helsinki residential areas
were identified between 1996 and 1999. After exclusion of
prevalent prostate cancer cases identified from national Finnish
Cancer Registry, a total of 80,144 men were randomly assigned
either to be screened with PSA at four-year intervals (the
screening arm, 31,866 men) or to control arm with no intervention
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and followed through national registries (48,278 men). The
screening finished in 2008, but the follow-up for cancer cases
in this study extended until the end of 2014. The available
information on prostate cancers were obtained trough study
database or through The Finnish Cancer Registry for men in the
control arm. The information included date of diagnosis, tumour
Gleason score, and tumour stage at diagnosis, recorded in this
study as non-metastatic (all M0 cases) and metastatic (all M1
cases).
The Finnish Cancer Registry is a nationwide registry collecting
information of cancer diagnoses from all Finnish health care units
and pathology laboratories through mandatory notifications. The
registry covers more than 99% of all cancer cases diagnosed in
Finland.14
To obtain information on BMI the participants of the third
screening round during 2004–2008 were mailed surveys asking
height and weight along with the screening invitations.15 This
information was available for 11,698 men in the FinRSPC cohort.
The study cohort was linked to a nationwide prescription
database of the Social Insurance Institution (SII) of Finland. The SII
is a governmental agency providing reimbursements for the cost
of physician-prescribed drugs to all Finnish citizens. From this
database we obtained information on usage of prescribed
antidiabetic drugs, antihypertensive drugs, statins, NSAIDs, and
aspirin during 1995–2009. Information on over-the-counter drug
purchases or on drugs administered during hospital inpatient
periods was not available.
Information on blood glucose level and glycated haemoglobin
The information on results from each measurement of fasting
plasma or blood glucose level and glycated haemoglobin (HbA1c)
performed at the Pirkanmaa region were obtained from the Fimlab
database and linked to the study cohort by using individual
identifier number. The data were available from 1978 for fasting
blood glucose level and from 1991 for HbA1c. Information
considering indication of blood glucose measurements was not
available, but it is most likely that these measurements are a mix of
standard health checks, age-dependent health checks, and control
measurements of diabetic men.
Fimlab Laboratories is one of the leading laboratory companies
in Finland.16 Fimlab provides laboratory services, education, and
research in Pirkanmaa, Central Finland, and Tavastia regions. A
major part of laboratory measurements in the Pirkanmaa region
are done in Fimlab laboratories. Approximately 25% of the
FinRSPC participants lived at Pirkanmaa region at baseline.
The study population of the FinRSPC study was linked to the
Fimlab database to identify men with at least one available
measurement of blood glucose and/or HbA1c during 1978–2015.
The information on fasting glucose levels and/or HbA1c levels
were available for 19,263 men, thus forming the cohort of this
study (Supplementary figure). The information on fasting glucose
levels or HbA1c levels were available for 17,860 and 11,736 men,
respectively. Each measured fasting glucose level was divided
into three categories: normoglycaemic if fasting glucose level
was under or equal to 6.0 mmol/l measured from plasma or under
or equal to 5.5 mmol/l measured from blood; pre-diabetic if
glucose level was between 6.0 and 7.0 mmol/l (plasma) or
between 5.6 and 6.1 mmol/l (blood), and diabetic if glucose level
was over 7.0 mmol/l (plasma) or over 6.1 mol/l (blood). The HbA1c
levels were also divided into three categories: normoglycaemic
if HbA1c was under 39 mmol/mol or under 5.7%, prediabetic
if HbA1c was between 39 and 47mmol/mol or between 5.7
and 6.4%, and diabetic if HbA1c level was over 47 mmol/mol or
over 6.4%.
Statistical analysis
We used Cox proportional hazards regression to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs) for overall risk of
Table 1. Population characteristics
Average fasting blood glucose level during
follow-up
Normoglycaemic Pre-diabetic Diabetic
n of men 8,481 5,812 3,567
FinRSPC study arm
Screening; n (%) 3,154 (37.2) 2,253 (38.8) 1,398 (39.2)
Control; n (%) 5,327 (62.8) 3,559 (61.2) 2,169 (60.8)
Median (IQR) follow-
up
17.0 (15.1–18.0) 16.3
(13.8–18.0)
15.3
(7.1–17.0)
n of PCa cases 808 454 401
Total follow-up time
(person years)
130,811 87,400 43,779
PCa incidence/1000
person years
6.18 5.19 9.16
Gleason score; n (%)
6 or less 409 (50.6) 215 (47.4) 203 (50.6)
7–10 384 (47.5) 230 (50.7) 189 (47.1)
Missing 15 (1.9) 9 (2.0) 9 (2.2)
Tumour stage; n (%)
Localised 759 (93.9) 410 (90.3) 374 (93.3)
Metastatic 48 (5.9) 44 (9.7) 25 (6.2)
Missing 1 (0.1) 0 (0.0) 2 (0.5)
Median (IQR) PSAa in
1st screening round 1.02 (0.62–1.76) 0.97
(0.61–1.69)
1.01
(0.58–2.06)
P for differenceb Ref 0.21 0.47
2nd screening round 1.30 (0.77–2.28) 1.23
(0.72–2.26)
1.16
(0.66–2.31)
P for differenceb Ref 0.13 0.01
3rd screening round 1.43 (0.81–2.49) 1.39
(0.77–2.41)
1.19
(0.67–2.24))
P for differenceb Ref 0.11 <0.001
Median (IQR) BMI 26.0 (24.2–28.3) 27.7
(25.3–30.6)
28.6
(26.2–31.6)
Antidiabetic
medication use; n (%)c
207 (2.4) 1,370 (23.6) 2,376 (66.6)
Pfor differenced Ref <0.001 <0.001
Statin use; n (%) 3,291 (38.8) 2,708 (46.6) 1,851 (51.1)
P for differenced Ref <0.001 <0.001
Antihypertensive drug
use; n (%)
5,481 (64.6) 4,387 (75.5) 2,917 (81.8)
P for differenced Ref <0.001 <0.001
NSAID use; n (%) 6,845 (80.7) 4,692 (80.7) 2,749 (77.0)
P for differenced Ref 0.98 <0.001
ASA use; n (%) 1,536 (18.1) 1,159 (19.9) 715 (20.0)
P for differenced Ref 0.006 0.013
5α-reductase inhibitor
use; n (%)
1,253 (14.8) 724 (12.5) 384 (10.8)
P for differenced Ref <0.001 <0.001
Study cohort of 17,860 men from the Finnish Randomized Study of
Screening for Prostate Cancer with at least one fasting blood/plasma
glucose measurement available during 1978–2014. aAll PSA values
measured are from men in the screening arm of the study. bP for
difference compared to the normoglycaemic group. Calculated with chi-
square test. cCategorisation based on average blood glucose level, thus
also users of antidiabetic drugs may be included in the normoglycaemic
group if they have good blood glucose control. dP for difference compared
to the normoglycaemic group. Calculated with Mann–Whitney U-test
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prostate cancer by fasting glucose and HbA1c levels. Analyses for
Gleason 6 or less, Gleason 7–10, non-metastatic and metastatic
tumours were performed separately. These separate analyses were
carried out in the same way as the overall analysis, but we only
included those PCa cases that met the specific criteria, and
calculated HRs between different groups for that cancer type. The
follow-up commenced from the FinRSPC randomisation (baseline)
and ended at the date of death, diagnosis of prostate cancer,
emigration, or end of the follow-up time (31 December 2014),
whichever came first. The time axis was years and month since the
baseline. The model was adjusted for age only (age-adjusted
analysis) and further for the FinRSPC study arm and the use of
antihypertensive drugs, cholesterol-lowering drugs, NSAIDs, and
aspirin (multivariable-adjusted model).
For each calendar year, we calculated the average yearly fasting
glucose and HbA1c levels based on all measurements within that
year. Fasting glucose level and HbA1c were analysed as time-
dependent variables, updated separately for each year after the
baseline. All men who did not have any glucose or HbA1c
measurement available in certain year was assigned to separate
missing-category for that year.
We further calculated the average blood glucose levels both
before and after initiation of antidiabetic drug use, i.e., the first
recorded purchase of any antidiabetic drug. Fasting glucose level
before and after antidiabetic drug use was analysed as time-
independent variables.
The association between fasting glucose level and prostate
cancer risk in subgroups was evaluated by repeating the analyses
after stratifying the study population by background variables.
Subgroup analyses were stratified by use of drugs that are
associated with metabolic syndrome and chronic inflammation.
We tested effect modification by adding an interaction term
between blood glucose level and the effect modifier into the Cox
regression model. The interaction term was considered statistically
significant if the p-value was ≤0.05.
The temporal association between fasting glucose level and
prostate cancer risk was evaluated by performing separate lag
time analysis for measurements done five, ten, fifteen, and twenty
years earlier.
We used IBM SPSS statistics software (version 23) to perform
Cox regression analyses. All p-values are two-sided.
Ethics approval of the study
The study has been approved by the ethics committee of the
Pirkanmaa Hospital District, decision number R10167.
RESULTS
Population characteristics
Of the 17,860 men, 8,481 were normoglycaemic, 5,812 were at the
pre-diabetic range, and 3,567 men were at the diabetic range of
fasting glucose (Table 1). During the median follow-up of 14.7
years after the baseline, a total of 1,663 prostate cancers were
diagnosed in the study cohort, 808 in the normoglycaemic group,
454 in the pre-diabetic group, and 401 in the diabetic group.
Median BMI in the diabetic group was non-significantly higher
compared to the normoglycaemic group.
The use of cholesterol-lowering drugs, antihypertensive drugs,
and aspirin was more common in the diabetic group compared to
the normoglycenic or pre-diabetic group. However, use of NSAIDs
and 5α-reductase inhibitors was less common in the diabetic
group (Table 1).
Median PSA was lower among diabetic men in all three FinRSPC
screening rounds compared to normoglycaemic men (Table 1).
Fasting blood glucose, HbA1c, and prostate cancer risk
Compared to the normoglycaemic men, overall PCa risk was
elevated in diabetic, but not in pre-diabetic men; multivariableT
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adjusted HR 1.52; 95% CI 1.31–1.75 (Table 2). The risk was similarly
elevated regardless of tumour Gleason score. However, the risk
elevation was limited to non-metastatic tumours; fasting blood
glucose level was not associated with risk of metastatic prostate
cancer (Table 2). Association between HbA1c levels and PCa risk
was not statistically significant. However, the number of men in
these analyses was low.
Effect modification by background variables
The connection between fasting glucose level and PCa risk was
affected by several background variables (Fig. 1). Diabetic blood
glucose level was associated with increased risk in the FinRSPC
screening arm, but not in the control arm (p for interaction <0.001).
The risk association was also modified by the use of antihyperten-
sive drugs; the association was weaker in users of these drugs (p for
interaction 0.018). Further, use of antidiabetic drugs generally and
in separate analysis metformin use abolished the risk association
(p for interaction <0.001). No clear effect modification by 5-ARI use
was observed, either (p for interaction 0.78).
Similar risk modifications were observed also for Gleason
score 8–10 tumours (Fig. 2). However, the interactions were not
statistically significant in this subgroup.
Role of change in fasting glucose levels after initiation of
antidiabetic drug use
Changes in fasting blood glucose levels after the initiation of
antidiabetic drug use were not associated with changes in
prostate cancer risk (Table 3). Similarly, no change in prostate
cancer risk was observed by changes in fasting glucose levels after
initiation of metformin use.
Long-term effects of fasting glucose levels
Blood glucose level measured 10 years earlier was borderline
significantly associated with elevated PCa risk as in our main
analysis; diabetic fasting glucose level was associated with increased
risk of non-metastatic tumours and Gleason 6 or less tumour
(Table 4). Similar, albeit non-significant risk increase were observed
also with 15-year lag time. However, no risk associations were
observed for the blood glucose levels measured two decades
earlier.
DISCUSSION
In this study we observed an association between fasting blood
glucose level and elevated prostate cancer risk. This association
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Fig. 1 Association between overall prostate cancer risk and blood glucose level in subgroup analysis. Study cohort of 17,860 men from the
Finnish Randomized Study of Screening for Prostate Cancer. Pre-D pre-diabetic, D diabetic blood glucose level. *P for interaction= 0.229 for
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was more noticeable in the screening arm, and concerned both
poorly and well-differentiated cancers. Previous studies suggest
that DM and use of antidiabetic drugs are associated with lowered
overall prostate cancer risk, while the risk of high-grade tumours
may be elevated.17–20 Our findings do not support the risk
lowering association for diabetes as a condition, as diabetic fasting
blood glucose levels were associated with increased, not lowered
prostate cancer risk. This supports the role of hyperglycaemia as a
prostate cancer risk factor. Nevertheless, use of antidiabetic drugs
abolished the risk increase observed with diabetic fasting blood
glucose level. Therefore, our study indirectly supports anticancer
effects of antidiabetic drugs, but the mechanism of action is
probably unrelated to blood glucose levels.
Some previous studies have reported association between
diabetes and lowered PSA compared to non-diabetic men.21–23
Concordantly, median PSA was lower also in our study. This would
presumably lead to lower incidence of PCa, as fewer prostate
biopsies would be performed due to PSA elevation. In a setting of
prostate cancer screening this would mean lower PCa incidence
among diabetic men especially in the FinRSPC screening arm. In
contrast, we observed a stronger association with increased PCa
risk in the FinRSPC screening arm, which suggests that prostate
cancer incidence among diabetic men is higher compared to non-
diabetic men even if the median PSA is lower. The risk elevation
seems to apply to all tumour grades as the risk elevation was
observed also for high-grade tumours.
A previous meta-analysis of 14 epidemiological studies found
increased risk of several cancer types for elevated HbA1c,
excluding prostate cancer.4 Concordantly, we did not observe
risk associations with HbA1c, only with fasting blood glucose
levels.
Another previous study has examined the association between
blood glucose and prostate cancer risk.24 In this case-cohort study
of 500 participants insulin concentrations and glucose concentra-
tions were determined from a single overnight fasting serum
sample 5 to 12 years before prostate cancer diagnosis. The study
suggests an association between PCa risk and elevated fasting
serum insulin, but not with elevated glucose levels. In contrast
to our study, the observed blood glucose levels were mainly in
the normal range, and no diabetic blood glucose levels were
Table 3. Impact of change in fasting blood glucose level after initiation of antidiabetic drug use
Prostate cancer risk
Overall Gleason 6 or less Gleason 7–10 Localised PCa Metastatic
n of men/PCa
cases
HR (95% CI)multivar.-
adjusted
a
HR (95% CI)multivar.-
adjusted
a
HR (95% CI)multivar.-
adjusted
a
HR (95% CI)multivar.-
adjusted
HR (95% CI)multivar.-
adjusted
a
Change in fasting blood glucose level
No change 427/43 Ref Ref Ref Ref Ref
Decrease 873/45 0.82 (0.49–1.36) 0.85 (0.39–1.84) 0.74 (0.37–1.47) 0.67 (0.38–1.20) 2.87 (0.87–9.50)
Increased 933/41 0.83 (0.55–1.26) 1.07 (0.59–1.93) 0.62 (0.34–1.13) 0.85 (0.54–1.29) 0.92 (0.23–3.68)
Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer. aMultivariable-adjusted analyses adjusted with age, the
FinRSPC study arm and use of antihypertensive drugs, statins, NSAIDs, or aspirin
Table 4. Association between the fasting blood glucose level 5, 10, 15, and 20 years earlier and prostate cancer risk
Prostate cancer risk
Overall Gleason 6 or less Gleason 7–10 Localised PCa Metastatic
HR (95% CI) multivar.-
adjusted’
HR (95% CI) multivar.-
adjusted’
HR (95% CI) multivar.-
adjusted’
HR (95% CI) multivar.-
adjusted’
HR (95% CI) multivar.-
adjusted’
Average fasting blood glucose level 5 years earlier
Normal Ref Ref Ref Ref Ref
Pre-diabetic 0.91 (0.70–1.17) 0.71 (0.47–1.07) 1.09 (0.78–1.52) 0.89 (0.68–1.17) 1.08 (0.47–2.50)
Diabetic 1.00 (0.78–1.27) 0.63 (0.42–0.94) 1.37 (1.01–1.88) 0.96 (0.74–1.17) 1.25 (0.56–2.76)
Average fasting blood glucose level 10 years earlier
Normal Ref Ref Ref Ref Ref
Pre-diabetic 1.27 (0.78–1.90) 0.63 (0.26–1.52) 1.70 (0.98–2.92) 1.16 (0.73–1.86) 1.97 (0.44–8.82)
Diabetic 1.34 (0.93–1.93) 1.62 (0.97–2.69) 1.31 (0.67–1.91) 1.41 (0.97–2.04) 0.38 (0.04–3.42)
Average fasting blood glucose level 15 years earlier
Normal Ref Ref Ref Ref Ref
Pre-diabetic 0.81 (0.34–1.92) 0.62 (0.14–2.68) 0.93 (0.32–2.76) 0.79 (0.31–2.05) 1.07 (0.12–9.59)
Diabetic 1.03 (0.58–1.82) 1.52 (0.70–3.27) 0.58 (0.23–1.50) 1.22 (0.68–2.20) —
Average fasting blood glucose level 20 years earlier
Normal Ref Ref Ref Ref Ref
Pre-diabetic 0.30 (0.04–2.20) 0.65 (0.08–5.07) — 0.32 (0.04–2.35) —
Diabetic 0.97 (0.41–2.32) — 1.78 (0.68–4.67) 0.90 (0.36–2.26) 1.51 (0.15–37.8)
Study cohort of 17,860 men from the Finnish Randomized Study of Screening for Prostate Cancer. Multivariable-adjusted analyses adjusted with age, the
FinRSPC study arm and use of antihypertensive drugs, statins, NSAIDs, or aspirin
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observed. Thus our results are in concordance with this previous
study, as we did not observe any risk increase even in men with
pre-diabetic blood glucose level, only among men at diabetic
glucose level.
The significance of blood glucose as PCa risk factor is supported
by our earlier findings in which we found a connection between
changes in genes associated to glucose metabolism and PCa
risk.5
Previously reported lower PCa risk among men with diabetes
could be explained by use of antidiabetic medication; for example
lower PCa risk has been reported among metformin users.25–28 In
this study the use of antidiabetic drugs abolished the observed
association between high blood glucose levels and elevated risk of
prostate cancer. This supports that the treatment of diabetes
could remove the risk increase associated with hyperglycaemia.
However, the changes in blood glucose level after initiation of
antidiabetic drug use during the follow-up was not connected to
PCa risk, which suggests that the possible antitumour effects of
antidiabetic drugs are mediated through mechanisms other than
blood glucose control. However, confirmation will be needed from
other studies as confidence intervals were relatively wide in our
risk estimates.
The association between blood glucose level and PCa risk is
likely to be long-term, because the elevated risk was observable
also for the fasting blood glucose level measured a decade earlier.
This suggests that diabetic glucose level could increase the risk of
initiation of prostate cancer development. To our knowledge this
is the first study to examine long-term associations between
fasting blood glucose and prostate cancer risk.
However, we did not observe risk associations by HbA1c
level, which reflects long-term glucose balance. HbA1c results
were available for fewer participants than were fasting glucose
measurements, thus these analyses were limited by lowered
statistical power. Nevertheless, this difference between the risk
associations between HbA1c and fasting glucose suggests that the
interaction between blood glucose, insulin and prostate cancer
may be complex.
Strengths of our study include large population-based cohort
and information on blood glucose measurements starting from
the 1980’s. We were also able to evaluate the effect of antidiabetic
drug on the risk association through comprehensive national
prescription database free of recall bias.
The study also has some limitations. We had no information on
lifestyle factors, such as smoking, diet, or physical activity, which
could possibly affect prostate cancer risk and cause confound-
ing.29–31 The available information on BMI was also limited.
Because of these factors, residual confounding is possible. Also,
because we had no information on the indication of blood glucose
measurements, selection bias is possible affecting the generalisa-
bility of our results. However, it does not limit our comparisons by
blood glucose level because all men with blood glucose
measurements available are prone to the same selection. Our
study population is almost entirely Caucasian due to homogeneity
of the Finnish population; thus our results may not be
generalisable to other ethnicities.
In conclusion, diabetic fasting blood glucose level is associated
with elevated PCa risk in a population-based cohort of Finnish
men, especially in the setting of systematic PSA-based
screening. The risk association is long-term, observed a decade
in advance of the diagnosis. Use of antidiabetic drugs removes
the risk association, supporting the risk lowering effect of these
drugs.
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